SRC and prostate cancer: Src promotes EMT by activating signaling pathways via phosphorylation events, leading to decreased E-cadherin expression, weakened cell-cell connection and by increasing mesenchymal marker expression, via phosphorylation events, e.g., in prostate cancer, breast cancer, pancreatic ductal carcinoma (Tatarov et al., 2009; Liu and Feng, 2010; Drake et al., 2012; Patel et al., 2016; Nagathihalli et al., 2012).